First Merchants Corp Amgen Inc Transaction History

First Merchants Corp

  • $1.42 Billion
  • Q3 2024

A detailed history of First Merchants Corp transactions in Amgen Inc stock. As of the latest transaction made, First Merchants Corp holds 12,209 shares of AMGN stock, worth $3.9 Million. This represents 0.28% of its overall portfolio holdings.

Number of Shares
12,209
Previous 12,365 1.26%
Holding current value
$3.9 Million
Previous $3.86 Million 1.81%
% of portfolio
0.28%
Previous 0.28%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 24, 2024
SELL
$309.38 - $337.38 $48,263 - $52,631
-156 Reduced 1.26%
12,209 $3.93 Million
Q2 2024

Jul 25, 2024
SELL
$262.75 - $319.31 $12,349 - $15,007
-47 Reduced 0.38%
12,365 $3.86 Million
Q1 2024

Apr 25, 2024
SELL
$268.87 - $324.56 $159,977 - $193,113
-595 Reduced 4.57%
12,412 $3.53 Million
Q4 2023

Jan 25, 2024
SELL
$255.7 - $288.46 $64,180 - $72,403
-251 Reduced 1.89%
13,007 $3.75 Million
Q3 2023

Oct 26, 2023
SELL
$218.65 - $271.46 $390,508 - $484,827
-1,786 Reduced 11.87%
13,258 $3.56 Million
Q2 2023

Jul 25, 2023
SELL
$214.27 - $253.37 $634,024 - $749,721
-2,959 Reduced 16.44%
15,044 $3.34 Million
Q1 2023

Apr 25, 2023
SELL
$225.79 - $275.2 $246,788 - $300,793
-1,093 Reduced 5.72%
18,003 $4.35 Million
Q4 2022

Jan 26, 2023
SELL
$229.03 - $291.01 $741,141 - $941,708
-3,236 Reduced 14.49%
19,096 $0
Q3 2022

Oct 25, 2022
SELL
$224.46 - $253.15 $18,405 - $20,758
-82 Reduced 0.37%
22,332 $5.03 Million
Q2 2022

Jul 26, 2022
SELL
$230.71 - $256.74 $15,688 - $17,458
-68 Reduced 0.3%
22,414 $5.45 Million
Q1 2022

Apr 26, 2022
BUY
$219.27 - $242.57 $26,750 - $29,593
122 Added 0.55%
22,482 $5.44 Million
Q4 2021

Jan 27, 2022
SELL
$198.88 - $227.6 $731,082 - $836,657
-3,676 Reduced 14.12%
22,360 $5.03 Million
Q3 2021

Oct 26, 2021
SELL
$212.27 - $248.7 $1.87 Million - $2.2 Million
-8,828 Reduced 25.32%
26,036 $5.54 Million
Q2 2021

Jul 26, 2021
BUY
$233.58 - $259.14 $80,585 - $89,403
345 Added 1.0%
34,864 $8.5 Million
Q1 2021

Apr 22, 2021
BUY
$221.91 - $258.6 $528,145 - $615,468
2,380 Added 7.41%
34,519 $8.59 Million
Q4 2020

Jan 28, 2021
BUY
$216.38 - $257.67 $701,720 - $835,623
3,243 Added 11.22%
32,139 $7.39 Million
Q3 2020

Oct 28, 2020
BUY
$234.65 - $260.95 $190,770 - $212,152
813 Added 2.89%
28,896 $7.34 Million
Q2 2020

Jul 23, 2020
BUY
$197.81 - $242.74 $271,790 - $333,524
1,374 Added 5.14%
28,083 $6.62 Million
Q1 2020

Apr 23, 2020
BUY
$182.24 - $241.7 $163,469 - $216,804
897 Added 3.48%
26,709 $5.41 Million
Q4 2019

Jan 30, 2020
BUY
$189.21 - $243.2 $195,832 - $251,712
1,035 Added 4.18%
25,812 $6.22 Million
Q3 2019

Oct 24, 2019
BUY
$174.11 - $208.62 $394,359 - $472,524
2,265 Added 10.06%
24,777 $4.8 Million
Q2 2019

Jul 25, 2019
BUY
$166.7 - $195.41 $139,861 - $163,948
839 Added 3.87%
22,512 $4.15 Million
Q1 2019

Apr 25, 2019
BUY
$180.87 - $203.88 $682,784 - $769,647
3,775 Added 21.09%
21,673 $4.12 Million
Q4 2018

Jan 31, 2019
BUY
$178.4 - $208.25 $80,993 - $94,545
454 Added 2.6%
17,898 $3.48 Million
Q3 2018

Oct 24, 2018
BUY
$185.29 - $208.89 $68,372 - $77,080
369 Added 2.16%
17,444 $3.62 Million
Q2 2018

Jul 26, 2018
BUY
$166.05 - $186.51 $664,698 - $746,599
4,003 Added 30.62%
17,075 $3.15 Million
Q1 2018

Apr 26, 2018
BUY
$169.43 - $198.0 $1.97 Million - $2.31 Million
11,648 Added 817.98%
13,072 $2.23 Million
Q4 2017

Jan 30, 2018
BUY
$168.79 - $188.59 $25,149 - $28,099
149 Added 11.69%
1,424 $248,000
Q3 2017

Oct 31, 2017
BUY
$167.29 - $191.0 $213,294 - $243,525
1,275
1,275 $238,000

Others Institutions Holding AMGN

# of Institutions
3,084
Shares Held
417M
Call Options Held
7.18M
Put Options Held
6.28M
View Full List

About AMGEN INC

AMGN Quotes by TradingView
  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $171B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track First Merchants Corp Portfolio

Follow First Merchants Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Merchants Corp, based on Form 13F filings with the SEC.

News

Stay updated on First Merchants Corp with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email